Jubilant Epicore LLC

Inipharm, Inc.

Subramanyam Janardhan Tantry

Athisayamani Jeyaraj Duraiswamy

Sridharan Rajagopal

Chandrika Mulakala

Sampath Kumar Anandan

Dhanalakshmi Sivanandhan

Purushottam Dewang

Vincent Florio

Joshua Odingo

Heather Kay Webb Hsu

Chandru Gajendran

Mohd Zainuddin

Sreekala Nair

Pravin Iyer

Kannan Murugan

Mahanandeesha S Hallur

Sriram K Rajagopal

Durga Prasanna Kumar C H

Durga Prasanna Kumar CH

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).

Dichlorophenol HSD17B13 inhibitors and uses thereof

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like. 

Growing community of inventors

Bengaluru, India

Subramanyam Janardhan Tantry